ATAI
Price
$1.18
Change
-$0.15 (-11.36%)
Updated
Dec 18, 04:59 PM (EDT)
99 days until earnings call
CYBN
Price
$9.41
Change
-$0.06 (-0.63%)
Updated
Dec 18, 04:59 PM (EDT)
Ad is loading...

ATAI vs CYBN

Header iconATAI vs CYBN Comparison
Open Charts ATAI vs CYBNBanner chart's image
ATAI Life Sciences
Price$1.18
Change-$0.15 (-11.36%)
Volume$2.33K
CapitalizationN/A
Cybin
Price$9.41
Change-$0.06 (-0.63%)
Volume$10.65K
CapitalizationN/A
ATAI vs CYBN Comparison Chart
Loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATAI vs. CYBN commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Hold and CYBN is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ATAI: $1.32 vs. CYBN: $9.47)
Brand notoriety: ATAI and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 73% vs. CYBN: 47%
Market capitalization -- ATAI: $221.5M vs. CYBN: $196.76M
ATAI [@Biotechnology] is valued at $221.5M. CYBN’s [@Biotechnology] market capitalization is $196.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileCYBN’s FA Score has 1 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • CYBN’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATAI and CYBN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 5 TA indicator(s) are bullish while CYBN’s TA Score has 4 bullish TA indicator(s).

  • ATAI’s TA Score: 5 bullish, 5 bearish.
  • CYBN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ATAI is a better buy in the short-term than CYBN.

Price Growth

ATAI (@Biotechnology) experienced а -13.73% price change this week, while CYBN (@Biotechnology) price change was -8.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

ATAI is expected to report earnings on Mar 27, 2025.

CYBN is expected to report earnings on Nov 13, 2024.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATAI($221M) has a higher market cap than CYBN($189M). ATAI YTD gains are higher at: -6.383 vs. CYBN (-39.217). ATAI (-124.33M) and CYBN (-130.23M) have comparable annual earnings (EBITDA) . CYBN has more cash in the bank: 154M vs. ATAI (85.9M). CYBN has less debt than ATAI: CYBN (133K) vs ATAI (23.8M). ATAI has higher revenues than CYBN: ATAI (331K) vs CYBN (0).
ATAICYBNATAI / CYBN
Capitalization221M189M117%
EBITDA-124.33M-130.23M95%
Gain YTD-6.383-39.21716%
P/E RatioN/AN/A-
Revenue331K0-
Total Cash85.9M154M56%
Total Debt23.8M133K17,895%
FUNDAMENTALS RATINGS
ATAI: Fundamental Ratings
ATAI
OUTLOOK RATING
1..100
80
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
15
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATAICYBN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 13 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSCGX33.58N/A
N/A
Goldman Sachs Large Cap Core A
IWTTX11.73-0.06
-0.51%
Voya Global High Dividend Low Vol PortS2
HFLGX11.54-0.06
-0.52%
Hennessy Cornerstone Large Growth Inv
HSZAX5.76-0.05
-0.86%
NexPoint Climate Tech A
JMEEX65.99-0.63
-0.95%
JPMorgan Mid Cap Equity R5

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with FATE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
-0.75%
FATE - ATAI
48%
Loosely correlated
-6.00%
ALLO - ATAI
45%
Loosely correlated
+0.49%
COUR - ATAI
45%
Loosely correlated
+1.49%
VCYT - ATAI
45%
Loosely correlated
-2.52%
MNMD - ATAI
44%
Loosely correlated
+1.08%
More

CYBN and

Correlation & Price change

A.I.dvisor tells us that CYBN and ATAI have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYBN and ATAI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-4.44%
ATAI - CYBN
33%
Poorly correlated
-0.75%
MNMD - CYBN
30%
Poorly correlated
+1.08%
SNPX - CYBN
30%
Poorly correlated
-1.99%
HEPA - CYBN
29%
Poorly correlated
-1.28%
CING - CYBN
25%
Poorly correlated
+0.99%
More